Concert squares up to Pfizer in alopecia Jak bout
Concert believes that high-dose data with CTP-543 will help it challenge Pfizer, but patent questions still loom large.
Xeljanz warning Jaks up safety concerns
An increased risk of blood clots and death with Pfizer’s drug could also bode ill for newer Jak inhibitors.
